Project Grant K08CA317035
- Federal Grant Award Summary The University of Pittsburgh received a $149,804 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded March 1, 2025, with completion scheduled for February 28, 2026. This award supports research investigating the impact of LAG3 (Lymphocyte Activation Gene 3) on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research builds upon preliminary findings demonstrating that...
- Federal Project Grant Award Summary The University of Pittsburgh received a $151,040 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective December 12, 2025, with completion targeted for November 30, 2027. This award supports biomedical training and research development focused on advancing cancer immunotherapy research. Specifically, the grant funds investigation into the relative and synergistic contributions of...
- Federal Project Grant Award Summary The University of Pittsburgh received $141,566 in funding through the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) under a K99/R00 career development award, effective March 24, 2026 through February 28, 2028. This project grant supports research training and workforce development focused on understanding small guanosine triphosphatase (GTPase) proteins, specifically RhoA, and their role in cancer pathogenesis. The research aims to...
- Summary of Federal Project Grant Award The University of Pittsburgh received a $379,644 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2028. The award funds research and development of cyclic peptide-based adaptors for universal Chimeric Antigen Receptor (CAR) T cell therapy. The project involves designing and synthesizing cyclic peptide adaptors to program SNAP-CAR T cells to recognize...
- Federal Project Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on March 13, 2026, with a completion date of February 29, 2028. This award supports fundamental research investigating immunosuppression mediated by regulatory CD8+ T cells in lung cancers. The project aims to profile and characterize KIR+CD8+ T cells (the human equivalent of LY49+CD8+ T...
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Pittsburgh a Project Grant of $217,600 under the Cancer Research Manpower program (CFDA 93.398) on September 17, 2025, with a completion date of March 31, 2029. This award supports research investigating the functional consequences of high glucose culture conditions on adoptive T cell therapies for cancer treatment. The project examines how standard in vitro expansion media—which contain approximately ten...
- Federal Grant Award Summary The University of Pittsburgh received a $125,783 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded July 7, 2026, with completion targeted for June 30, 2028. The award funds the development and evaluation of RUCAS (Rural Cancer Survivorship), a personalized, place-based digital health intervention designed to promote physical activity adherence among cancer survivors in rural areas. This initiative...
- Federal Project Grant Award Summary The University of Pittsburgh received a $164,190 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded January 21, 2026, with completion targeted for July 31, 2029. This award funds research into metastatic breast cancer subclone tracking through an innovative integration of machine learning and comprehensive autopsy data. The project will deliver computational analysis of DNA structural...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration within the School of Medicine a Project Grant totaling $109,076.00 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025. The award supports biomedical research training and career development initiatives focused on cancer research through September 1, 2029. This project grant funds the institution's capacity to provide integrated...
The National Cancer Institute (NCI) awarded the University of Pittsburgh a $214,726 Career Development Project Grant under the Cancer Research Manpower program (CFDA 93.398) effective July 17, 2026, with completion targeted for June 30, 2031. This award supports an investigator's career development in cancer immunology, specifically focusing on transforming growth factor beta (TGF-β) regulation of immune evasion and metastasis in Ewing sarcoma. The primary deliverables include conducting preclinical research utilizing an immunocompetent humanized mouse model of Ewing sarcoma to investigate TGF inhibition during radiation therapy as a mechanism to enhance chimeric antigen receptor (CAR) T cell therapy efficacy in patients with metastatic or relapsed disease. The award funds the investigator's acquisition of advanced technical competencies in single-cell and spatial RNA sequencing analysis, flow cytometry, and preclinical CAR T cell testing, with mentorship provided by a world-renowned cancer immunologist (primary mentor) and an Ewing sarcoma biology expert (co-mentor). The research addresses a critical clinical need, as patients with metastatic or relapsed Ewing sarcoma currently experience poor outcomes; proposed findings are intended to overcome immune infiltration barriers and immunosuppressive cytokine effects that limit CAR T cell therapeutic success in this patient population.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $214.7k | 7/17/26 |